Monday, November 27, 2006 3:52:32 AM
For me the main question is: How big is the probability that
DOR gets orBEC approved? IF yes they could receive money from
licensing fees for their European permission and sell orBEC
in the USA for themself. The problem is dilution. But it seems
that they are not big money burners until now. Is it more probable that they get European permission? A lot of good questions. For to have more success they need to change the
stock exchange. But this can happen later...
Much fantasy, much risk, much potential....
DOR gets orBEC approved? IF yes they could receive money from
licensing fees for their European permission and sell orBEC
in the USA for themself. The problem is dilution. But it seems
that they are not big money burners until now. Is it more probable that they get European permission? A lot of good questions. For to have more success they need to change the
stock exchange. But this can happen later...
Much fantasy, much risk, much potential....
Recent SNGX News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/03/2026 04:15:15 AM
- Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy • PR Newswire (US) • 04/02/2026 11:30:00 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:13:29 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:11:25 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:09:30 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:08:14 PM
- Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results • PR Newswire (US) • 03/31/2026 11:30:00 AM
- Soligenix secures EU orphan drug designation for Behçet’s disease therapy • IH Market News • 03/26/2026 02:15:07 PM
- Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease • PR Newswire (US) • 03/26/2026 11:30:00 AM
- HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 • PR Newswire (US) • 03/23/2026 11:30:00 AM
- IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc. • GlobeNewswire Inc. • 03/19/2026 12:00:00 PM
- Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs" • PR Newswire (US) • 03/19/2026 11:30:00 AM
- Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency • PR Newswire (US) • 03/10/2026 11:30:00 AM
- Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease • PR Newswire (US) • 02/26/2026 12:30:00 PM
- Soligenix to Present at BIO Investment & Growth Summit • PR Newswire (US) • 02/24/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2026 09:05:19 PM
- Soligenix Details Recent Progress and Upcoming Milestones • PR Newswire (US) • 02/12/2026 12:30:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/23/2026 09:31:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2026 09:05:35 PM
- Soligenix Shares Jump on Encouraging Data for Behçet’s Disease Therapy • IH Market News • 12/18/2025 03:30:21 PM
- Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) • PR Newswire (US) • 12/18/2025 12:30:00 PM
